The Palpable Prostate

Prostate cancer topics, links and more. Now at 100+ posts!

News: Health Day, Medical News Today, ScienceDaily, Urol Times, Urotoday, Zero Cancer Papers: Pubmed (all), Pubmed (Free only), Amedeo
Journals: Eur Urol, J Urol, JCO, The Prostate Others Pubmed Central Journals (Free): Adv Urol, BMC Urol, J Endourol, Kor J Urol, Rev Urol, Ther Adv Urol, Urol Ann
Reviews: Cochrane Summaries, PC Infolink Newsletters: PCRI, US Too General Medical Reviews: f1000, Health News Review
Loading...

Monday, June 30, 2014

Updates for June 2014

June 16, 2014. We added this update link to the Commonwealth report under Benchmarking in the Links list to the right. (2014)

Monday, June 2, 2014

Updates for May 2014

May 29, 2014. In Prostate Cancer Calculators we added: Lifespan. The Project Big Life site has a life expectancy calculator based on diet, smoking status and exercise. There are also calculators to estimate how many days in the hospital you will spend over you lifetime and a salt intake calculator.

Saturday, May 3, 2014

Updates for April 2014

April 17, 2014. In Yananow Case History Links and Depth of Presentation and in Yananow Place Name Table an interactive view has been added that lets readers sort and filter the tables on any column.
April 13, 2014. Added to the Guideline section in the right margin: [AUA SRT 2013]. [ACR SRT 2010]

Tuesday, April 1, 2014

Updates for March 2014

March 13, 2014. Under Benchmarking to the right we added a link to the US Senate subcommittee hearing on Health Care in Other Countries: http://www.help.senate.gov//hearings/hearing/?id=8acab996-5056-a032-522e-e39ca45fcfbe

Friday, February 28, 2014

Updates for February 2014

In Advice to the Newly Diagnosed we added:
2014 Swedish Study. An observational study of 34,515 men over 15 years (from 1996 to 2010) found that for men with metastatic prostate cancer survival was similar among the surgery and radiation groups; however, for men with non-metastatic prostate cancer survival was better among patients who had surgery relative to those who had had radiation (particularly among younger and healthier men). This is summarized in Fig. 2. [PMID: 24574496] [Full free text].

Thursday, January 30, 2014

Updates for January 2014

Jan 25, 2014. In Biochemical PSA Recurrence we added: Itraconazole. A 2013 John Hopkins study found that among 29 men with of metastatic castration-resistant prostate cancer taking 600 mg/day of the drug itraconazole (which is currently approved in the US as an antifungal and is also known as Onmel® or Sporanox®) resulted in no PSA progression in 14 of 29 high dose subjects at 24 weeks. The high dosage seems essential as among 17 men in a low dose arm (200 mg/day) it was found to be ineffective and that part of the study terminated early. This and previous test tube and animal studies (see references 11-16 in paper) found that the mechanism of action is to inhibit angiogenesis and Hedgehog signaling. The researchers concluded that the high dose regimen has "has modest antitumor activity". Side effects included fatigue, nausea, anorexia, rash, and a syndrome of hypokalemia, hypertension, and edema. Additional side effects are listed here. There are a number of drugs which should not be taken with Itraconazole. See Wikipedia. The abstract and full paper are available here: [PMID: 23340005] [Full paper].